Polar Capital’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Polar Capital’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-409,582	Closed	-$13.6M	–	294
2018 Q3	$13.6M	Sell	409,582 -345,685	-46%	-$8.88M	0.12%	169
2018 Q2	$17.1M	Sell	755,267 -32,476	-4%	-$770K	0.1%	167
2018 Q1	$22.8M	Sell	787,743 -20,000	-2%	-$585K	0.23%	133
2017 Q4	$22.5M	Buy	807,743 +394,819	+96%	+$12.3M	0.23%	126
2017 Q3	$15.1M	Buy	+412,924	New	+$12.8M	0.17%	142

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Polar Capital's AVEO Position: Q4 2018 in Review

Polar Capital sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2018, closing a stake of 409,582 shares — an estimated $13.6M sold.

Polar Capital first reported a position in AVEO in Q3 2017 and held it in 5 quarters. The position peaked at $22.8M in Q1 2018. 99 funds tracked by Wall St. Rank hold AVEO as of Q4 2018.

Polar Capital reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Polar Capital sold 409,582 AVEO Pharmaceuticals, Inc. shares in Q4 2018, an estimated $13.6M.
Polar Capital first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2017 and held it in 5 quarters.
Polar Capital's AVEO Pharmaceuticals, Inc. position peaked at $22.8M in Q1 2018.
99 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2018.

Based on Polar Capital's 13F filing for Q4 2018, filed 14 Feb 2019.